Ya Hwee Tan
@yahwee_t
Followers
68
Following
266
Media
0
Statuses
70
Medical Oncologist @nccsingapore | Graduate Student MSc Immunology @UniofOxford | EDD Fellow @PeterMacCC| Interests in Cancer Immunology and Cell Therapy
Melbourne, Victoria
Joined August 2022
RT @aaronmring: T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a rā¦.
0
109
0
Blazing-fast image creation ā using just your voice. Try Grok Imagine.
15
18
141
RT @NatureCancer: šAnother timely Review @NatureCancer, by G. Dotti and collaborators š.
nature.com
Nature Cancer - Dotti and colleagues review chimeric antigen receptor (CAR)-engineered cell-based cancer therapy and overview its transition for solid tumors from CAR T to CAR-engineered innate...
0
28
0
RT @NatureCancer: Check out a new Review article on clonal hematopoiesis by Jen Trowbridge and collaborators @NatureCancer ..
nature.com
Nature Cancer - Trowbridge and colleagues provide a comprehensive review of clonal hematopoiesis in diverse cancer settings, from myeloid malignancies to solid tumors, covering underlying molecular...
0
10
0
RT @NatureMedicine: Our latest Review summarizes the current knowledge on mortality-defining toxicities of #CARTcell therapies, beyond CRSā¦.
0
11
0
RT @celltherapynews: This @CellRepMed review addresses the integration of CAR-T cell therapy with reconstructive oncologic surgery in treatā¦.
0
3
0
A pleasant surprise this weekend ā this book was a post-date labour from the COVID era, but itās finally been delivered at last! š¬.
link.springer.com
0
0
1
RT @HindRafei: š§µ1/.T cells have deservedly been in theš¦for #cancer #immunotherapy, but other engineered cell therapies are nowš. What mediaā¦.
0
105
0
Itās timely commentary at this age that IL-2 is back in the clinic, but itās causing anxiety among the clinicians.
New #JITC commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy @bbuchbinderMD @kmargolin @DrBetofMDPhD
0
0
1
Gut microbiome, circadian rhythm-based ICI dosingāthis era, weāre living IO.
The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development This new Review highlights key advances in clinical microbiome characterization and their implications for immunotherapy #ASCO2025
0
0
1
RT @celltherapynews: Take a look at the next innovations in CAR T cell immunotherapies for cancer! . Enjoy reading this review by Dr. Levinā¦.
0
5
0
Good to see emerging strategies targeting BTK, MEK, and PI3KāAKTāmTOR pathways to mitigate toxicity & augment CAR-T cell stemness. Metabolic targeting is plausible over manipulating hematopoiesis, hopefully comes with less cytopenias and infections.
0
0
1
Tackling my first scientific academic writing challenge was no small feat, and Iām grateful for the opportunity to contribute under the mentorship of the fieldās most brilliant minds @HaanenJohn & team š. Expanding TILs beyond melanoma .
0
0
4
Han Yi flying the @nccsingapore flag high at ESMO Breast š.
Dr Han Yi Lee was interviewed at #ESMOBreast25 on the results #328P of the BIG international physician survey on HER2 targeted therapy for mBC long-term survivors #BCSM
0
0
1
Since I am going to study vaccine this term, I guess cancer vaccine feels like the right way to tune in š.
NEW content online! Recent advances in therapeutic cancer vaccines
0
0
1
Timely breakthrough while I am studying the IEI unit, gene therapy shines for IEIs beyond supportive care. But the key lies in scaling access to bespoke cures for many, if not all.
nejm.org
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
0
0
0
NK-based therapy is one step closer to the clinic! . After spending the a good few months researching NK cells for my essay, itās encouraging to see developments like this one š #NK #ADCC.
A promising phase 1 trial in patients with refractory #Hodgkinlymphoma underscores the potential value of allogeneic natural killer (NK) #celltherapy guided by NK cell-specific engagers. News & Views from Karl-Johan Malmberg, Ebba Sohlberg.
0
0
1
IL-18 making to the clinic! And 3 days manufacturing š¤©. huCART19-IL18 is primed to storm the CAR-T landscape šŖļø.
CD19-specific CAR T cells engineered to secrete interleukin-18 were used to treat patients with lymphoma after previous CAR T failure, with a complete or partial response of 81% and a complete response of 52%. Full trial results:
0
0
0